Ionis Pharmaceuticals, Inc.
IONS
$55.34
-$0.68-1.21%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 874.09M | 1.06B | 943.71M | 966.96M | 944.05M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 874.09M | 1.06B | 943.71M | 966.96M | 944.05M |
| Cost of Revenue | 929.60M | 934.86M | 923.93M | 885.65M | 886.39M |
| Gross Profit | -55.51M | 123.33M | 19.78M | 81.31M | 57.67M |
| SG&A Expenses | 537.95M | 474.48M | 400.37M | 358.26M | 323.09M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 900.00K | 1.10M | 1.10M | 1.10M | 1.10M |
| Total Operating Expenses | 1.47B | 1.41B | 1.33B | 1.25B | 1.21B |
| Operating Income | -594.36M | -352.25M | -381.69M | -278.05M | -266.52M |
| Income Before Tax | -562.00M | -325.09M | -379.60M | -258.72M | -274.43M |
| Income Tax Expenses | 3.17M | 1.89M | 1.79M | -2.38M | -6.22M |
| Earnings from Continuing Operations | -565.17 | -326.98 | -381.39 | -256.34 | -268.22 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -565.17M | -326.98M | -381.39M | -256.34M | -268.22M |
| EBIT | -594.36M | -352.25M | -381.69M | -278.05M | -266.52M |
| EBITDA | -579.49M | -338.65M | -369.24M | -266.80M | -255.17M |
| EPS Basic | -3.48 | -2.01 | -2.37 | -1.61 | -1.76 |
| Normalized Basic EPS | -2.26 | -1.32 | -1.45 | -1.05 | -1.04 |
| EPS Diluted | -3.48 | -2.08 | -2.45 | -1.69 | -1.83 |
| Normalized Diluted EPS | -2.26 | -1.39 | -1.52 | -1.12 | -1.11 |
| Average Basic Shares Outstanding | 652.06M | 645.78M | 639.64M | 635.64M | 624.47M |
| Average Diluted Shares Outstanding | 652.06M | 668.97M | 662.83M | 658.83M | 647.66M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |